RECRUITING

Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease (DED)

Official Title

A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)

Quick Facts

Study Start:2023-12-29

Study Completion:2024-07-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06178679

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Be at least 18 years of age; 2. Provide written informed consent; 3. Have a reported history of DED for at lease 6 months prior to Visit 1; 4. Have a history of use or desire to use eye drops for DED within 6 months of Visit 1; 5. Report a score of ≥ 2 on the Ora Calibra® Ocular Discomfort \& 4-symptom questionnaire in at least one symptom pre-CAE® at Visits 1 and 2; 6. Have a Schirmer's Test score of ≤ 10 mm and ≥ 1 mm at Visits 1 and 2; 7. Have a conjunctival redness score ≥ 1 according to the Ora Calibra® Conjunctival Redness for Dry Eye Scale in at least one eye at pre-CAE® Visits 1 and 2; 8. Have a corneal fluorescein staining score of ≥ 2 in at least one region (e.g. inferior, superior, or central) pre-CAE® at Visits 1 and 2; 9. Have a sum corneal fluorescein staining score of ≥ 4, based on the sum of the inferior, superior, and central regions pre-CAE®, at Visits 1 and 2; 10. Have a total lissamine green conjunctival score of ≥ 2, based on the sum of the temporal and nasal regions pre-CAE® at Visits 1 and 2; 11. Demonstrates a response to the CAE® at Visits 1 and 2 as defined by: 12. Have at lease one single eye satisfy all criteria for 6, 7, 8, 9, 10 and 11 above.	1. Have any clinically significant slit lap findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction, lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters; 2. Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1; 3. Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study; 4. Have used any eye drops within 2 hours of Visit 1; 5. Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months; 6. Have used Restasis®, Xiidra®, or Cequa® ophthalmic solutions Tyrvaya® nasal spray, or Miebo® or Xdemvy® solution within 45 days of Visit 1; 7. Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within the last 6 months; 8. Have used, are using or anticipate using permanent or temporary punctal plugs during the study within 90 days of Visit 1; 9. Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter solutions, artificial tears, gels or scrubs, or using a moisture chamber and cannot discontinue these medications for the from Visit 1 until after Visit 8 of the trial (excluding medications allowed for the conduct of the study); 10. Be currently taking or have taken Omega-3 supplements within the last 3 months; 11. Be currently taking of have taken CHANTIX® (varenicline) tablets within 6 months prior to Visit 1 that is not on a stable dose. The dose cannot change during the conduct of the study; 12. Have corrected visual acuity (VA) greater than or equal to logarithm of the Minimum Angle of Resolution (logMAR) +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1; 13. Be a woman who is pregnant, nursing, or planning a pregnancy during the study; 14. Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 8 (or early termination visit) if of childbearing potential. Non-childbearing potential is defined as a woman who is permanently sterilized (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 months prior to dosing), or is post-menopausal (where post-menopausal is defined as no menses for 12 months without an alternative medial cause); 15. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception includes: hormonal - oral, implantable, injectable, or transdermal contraceptives for at least one month prior to first visit; Use two of the following effective methods of contraception: intrauterine device (IUD without local hormone release), diaphragm, cervical cap, and/or condoms; or surgical sterilization of partner (i.e., a female participant's male partner has undergone effective surgical sterilization such as vasectomy before the female participant entered the clinical trial) who has obtained documentation of absence of sperm in his ejaculate and is the sole sexual partner of the female participant during the clinical trial. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study; 16. Have a known allergy and/or sensitivity to the Study Drug or its components; 17. Have a condition or be in a situation that the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study; 18. Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1; 19. Be currently using any medication known to cause ocular drying that is not used on a stable dosing regimen for the least 30 dats prior to Visit 1; 20. Have a known history of meibomian gland procedures (e.g. LipiFlow, laser peripheral iridotomy (LPI), probing, etc.) within 6 months of study enrollment; 21. Be unable or unwilling to follow instructions, including participation in all study assessments and visits; 22. Has participated in any other clinical trials of ophthalmologic drugs for 30 days before or during participation in this Study.

Inclusion Criteria

Exclusion Criteria

1. Be at least 18 years of age;
2. Provide written informed consent;
3. Have a reported history of DED for at lease 6 months prior to Visit 1;
4. Have a history of use or desire to use eye drops for DED within 6 months of Visit 1;
5. Report a score of ≥ 2 on the Ora Calibra® Ocular Discomfort \& 4-symptom questionnaire in at least one symptom pre-CAE® at Visits 1 and 2;
6. Have a Schirmer's Test score of ≤ 10 mm and ≥ 1 mm at Visits 1 and 2;
7. Have a conjunctival redness score ≥ 1 according to the Ora Calibra® Conjunctival Redness for Dry Eye Scale in at least one eye at pre-CAE® Visits 1 and 2;
8. Have a corneal fluorescein staining score of ≥ 2 in at least one region (e.g. inferior, superior, or central) pre-CAE® at Visits 1 and 2;
9. Have a sum corneal fluorescein staining score of ≥ 4, based on the sum of the inferior, superior, and central regions pre-CAE®, at Visits 1 and 2;
10. Have a total lissamine green conjunctival score of ≥ 2, based on the sum of the temporal and nasal regions pre-CAE® at Visits 1 and 2;
11. Demonstrates a response to the CAE® at Visits 1 and 2 as defined by:
12. Have at lease one single eye satisfy all criteria for 6, 7, 8, 9, 10 and 11 above.

1. Have any clinically significant slit lap findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction, lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
2. Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
3. Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
4. Have used any eye drops within 2 hours of Visit 1;
5. Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
6. Have used Restasis®, Xiidra®, or Cequa® ophthalmic solutions Tyrvaya® nasal spray, or Miebo® or Xdemvy® solution within 45 days of Visit 1;
7. Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within the last 6 months;
8. Have used, are using or anticipate using permanent or temporary punctal plugs during the study within 90 days of Visit 1;
9. Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter solutions, artificial tears, gels or scrubs, or using a moisture chamber and cannot discontinue these medications for the from Visit 1 until after Visit 8 of the trial (excluding medications allowed for the conduct of the study);
10. Be currently taking or have taken Omega-3 supplements within the last 3 months;
11. Be currently taking of have taken CHANTIX® (varenicline) tablets within 6 months prior to Visit 1 that is not on a stable dose. The dose cannot change during the conduct of the study;
12. Have corrected visual acuity (VA) greater than or equal to logarithm of the Minimum Angle of Resolution (logMAR) +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1;
13. Be a woman who is pregnant, nursing, or planning a pregnancy during the study;
14. Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 8 (or early termination visit) if of childbearing potential. Non-childbearing potential is defined as a woman who is permanently sterilized (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 months prior to dosing), or is post-menopausal (where post-menopausal is defined as no menses for 12 months without an alternative medial cause);
15. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception includes: hormonal - oral, implantable, injectable, or transdermal contraceptives for at least one month prior to first visit; Use two of the following effective methods of contraception: intrauterine device (IUD without local hormone release), diaphragm, cervical cap, and/or condoms; or surgical sterilization of partner (i.e., a female participant's male partner has undergone effective surgical sterilization such as vasectomy before the female participant entered the clinical trial) who has obtained documentation of absence of sperm in his ejaculate and is the sole sexual partner of the female participant during the clinical trial. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study;
16. Have a known allergy and/or sensitivity to the Study Drug or its components;
17. Have a condition or be in a situation that the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;
18. Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1;
19. Be currently using any medication known to cause ocular drying that is not used on a stable dosing regimen for the least 30 dats prior to Visit 1;
20. Have a known history of meibomian gland procedures (e.g. LipiFlow, laser peripheral iridotomy (LPI), probing, etc.) within 6 months of study enrollment;
21. Be unable or unwilling to follow instructions, including participation in all study assessments and visits;
22. Has participated in any other clinical trials of ophthalmologic drugs for 30 days before or during participation in this Study.

Contacts and Locations

Study Contact

George Ousler

CONTACT

9786858900

gousler@oraclinical.com

Study Locations (Sites)

Total Eye Care, PA

Memphis, Tennessee, 38119

United States

Collaborators and Investigators

Sponsor: ORA, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-29

Study Completion Date2024-07-30

Study Record Updates

Study Start Date2023-12-29

Study Completion Date2024-07-30

Terms related to this study

Additional Relevant MeSH Terms

Dry Eye Disease